{"id":"NCT03959488","sponsor":"AstraZeneca","briefTitle":"A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children","officialTitle":"A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-07-30","primaryCompletion":"2021-05-03","completion":"2023-01-20","firstPosted":"2019-05-22","resultsPosted":"2023-09-21","lastUpdate":"2023-09-21"},"enrollment":925,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Respiratory Syncytial Virus Infections"],"interventions":[{"type":"DRUG","name":"MEDI8897","otherNames":[]},{"type":"DRUG","name":"Palivizumab","otherNames":[]}],"arms":[{"label":"MEDI8897","type":"EXPERIMENTAL"},{"label":"Palivizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.","primaryOutcome":{"measure":"Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)","timeFrame":"360 days post first dose","effectByArm":[{"arm":"MEDI8897","deltaMin":444,"sd":null},{"arm":"Palivizumab","deltaMin":215,"sd":null},{"arm":"MEDI8897/MEDI8897","deltaMin":130,"sd":null},{"arm":"Palivizumab/MEDI8897","deltaMin":31,"sd":null},{"arm":"Palivizumab/Palivizumab","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"0 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":128,"countries":["United States","Austria","Belgium","Bulgaria","Canada","Czechia","Estonia","Finland","France","Germany","Hungary","Italy","Japan","Latvia","Lithuania","Mexico","New Zealand","Poland","Russia","South Africa","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["35235733"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00005&amp;attachmentIdentifier=7817621f-6d8e-41e6-a839-c1ccdfed21c7&amp;fileName=d5290c00005-study-synopsis.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00005&amp;attachmentIdentifier=ba02bb70-712d-4844-908a-a17816e1e918&amp;fileName=D5290C00005-Protocol.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5290C00005&amp;attachmentIdentifier=1ed84f06-335c-4887-8739-15ccaa840cb3&amp;fileName=D5290C00005-SAP.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":614},"commonTop":["Upper respiratory tract infection","Pyrexia","Rhinitis","Nasopharyngitis","Viral upper respiratory tract infection"]}}